Research studies conducted with cancer patients are called clinical trials. As a cancer patient, you may take part in a clinical trial.
Please see the links below for current open trials at UC San Francisco.
| Immunotherapy | Neuroendocrine | Non-therapeutic | Pancreatic
Opening Soon | All Cancer Trials at UCSF
COLORECTAL
CC#174517: Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Microsatellite Stable Metastatic Colorectal Cancer
Contact: Renee Wang (415) 514-6258: [email protected]
CC#197016: A Phase 1A/1B, Open-Label First-In-Human Study of the Safety, Tolerability, and Feasibility of Gene-Edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination with ANTI-PD-1 to Patients with Locally Advanced or Metastatic Solid Tumors
Contact: Marissa Gin (415) 476-3816: [email protected]
Not currently enrolling
AMC095: A Phase 1 Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors
Contact: Yuwen Jian: [email protected]
CC#19958: First-In-Human, Open-Label, Phase I Dose Escalation and Cohort Expansion Study of BB-1701 in Locally Advanced/Metastatic Her2 Expressing Solid Tumors
Contact: Amrutha Sugetur: [email protected]
CC#18956: A Phase 1B Dose Escalation/Expansion Study of Abexinostat in Combination with Pembrolizumab in Patients with Advanced Solid Tumor Malignancies
Contact: Shabana Akramy (415) 514-6674: [email protected]
CC#189510: A Phase II Trial of AZD6738 Alone and in Combination with Olaparib in Patients with Selected Solid Tumor Malignancies
Contact: Michelle Howell (415) 514-6248: [email protected]
CC#189513: A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and IN combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma
Contact: Amrutha Sugetur: Amrutha.[email protected]
CC#189514: A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants with Relapsed/Refractory Solid Tumors RMC-4630 is a potent, selective, and orally bioavailable SHP2 allosteric inhibitor that is being developed for patients with tumors harboring certain activating mutations or other genotypic aberrations in the RAS–MAPK pathway, including upstream mutations in RTKs.
Contact: Amrutha Sugetur: [email protected]
CC#19954: A Phase 1 Multicenter, Open-Label, Dose-Escalation an Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of AO_176
Contact: Amrutha Sugetur: [email protected]
CC#19955: Protocol 101-18101 – An Open Label Phase 1b Study of ORIC-101 in Combination with Anticancer Therapy in Patients with Advanced or Metastatic Solid Tumors
Contact: Shabana Akramy (415) 514-6674: [email protected]
CC#19956: Protocol RMC 4360 02: A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 in combination with Cobimetinib in Adult Participants with Relapsed/Refractory Solid Tumors
Contact: Amrutha Sugetur: [email protected]
CC#199511: A Phase 1/2 Study of CYT-0851 (a RAD51 inhibitor) in Patients with Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
Contact: Yuwen Jian: [email protected]
CC#199516: Phase 1/1b Study of TPST-1120 () as Single Agent or w/Systemic Anti-Cancer Therapies in Patients with Advanced Solid Tumors
Contact: Nela Pawlowksa: [email protected]
CC#209511: A first in human study of highly selective FGFR2 inhibitor, RLY-4008 in patients with intrahepatic cholangiocarcinoma (ICC)
Contact: Michelle Howell (415) 514-6248: [email protected]
CC#209517: A Phase 1/2 Trial of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation
Contact: Shabana Akramy (415) 514-6674: [email protected]
CC#20958: A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination with Dabrafenib for the treatment of Advanced Solid Tumors with MAPK Pathway Mutations
Contact: Nela Pawlowksa: [email protected]
Not currently enrolling
CC#20959: A Phase 1/2 Open Label, Dose Escalation, and Cohort Expansion of Clinical Trial of ARV-471 Alone and in Combination with Palbociclib (IBRANCE) in Patients with ER+/HER- Locally Advanced or Metastatic Breast Cancer
Contact: Swati Sudarsan 415-476-3761: [email protected]
GASTRO ESOPHAGEAL
CC#17701: A Phase 2 Study of APX005M in Combination with Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers
Contact: Marissa Gin (415) 476-3816: [email protected]
CC#18453: A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-Line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Contact: Nancy Kaushal (415) 514-7633: [email protected]
CC#204520: A Phase 2a, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)
Contact: Taylor Sanchez (415) 885-7740: [email protected]
HEPATOCELLULAR and BILIARY TRACT
An Open-Label, Expanded Access Program of FUTIBATINIB in Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Contact: Ashna Sethi (415) 353-1745: [email protected]
CC#197010: A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer
Contact: Carolyn Bridgman (415) 514-7975: [email protected]
CC#174523: Multicenter Pilot Study of the Safety, Efficacy, and Immune Cell
Profiling in Advanced Hepatocellular Carcinoma (HCC) Patients Treated with the Combination of Sorafenib plus Nivolumab as First-Line of Systemic Therapy
Contact: Maxine Hamilton (415) 476-3755: [email protected]
IMMUNOTHERAPY
CC#17701: A Phase 2 Study of APX005M in Combination with Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers
Contact: Marissa Gin (415) 476-3816: [email protected]
CC#17705: A Pilot Study of Pembrolizumab and Liver Directed Therapy or Peptide Receptor Radionuclide Therapy for Patients with Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases.
Contact: Chris De Leon (415) 476-2958: [email protected]
CC#187011: A Phase 1/1b Multicenter Study to Evaluate the Humanized Anti-CD73 Antibody, CPI-006, as a Single Agent or in Combination with Ciforadenant, with Pembrolizumab, and with Ciforadenant Plus Pembrolizumab in Adult Subjects with Advanced Cancers
Contact: Allegra Koch (415) 476-2381: [email protected]
Not currently enrolling
CC#197016: A Phase 1A/1B, Open-Label First-In-Human Study of the Safety, Tolerability, and Feasibility of Gene-Edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination with ANTI-PD-1 to Patients with Locally Advanced or Metastatic Solid Tumors
Contact: Marissa Gin (415) 476-3816: [email protected]
Not currently enrolling
CC#19704 Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination with Pembrolizumab or Chemotherapy in Patients with Lymphoma or Solid Tumor Malignancies
Contact: Maria Conti (415) 514-2259: [email protected]
CC#197010: A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer
Contact: Carolyn Bridgman (415) 514-7975: [email protected]
CC#207021: A Phase 1 Study of SRF388 in Patients with Advanced Solid Tumors
Contact: Chris De Leon (415) 476-2958: [email protected]
Not actively accruing, contact study CRC for more information
NEUROENDOCRINE TUMORS
CC#17705: A Pilot Study of Pembrolizumab and Liver-Directed Therapy or Peptide Receptor Radionuclide Therapy for Patients with Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases
Contact: Chris De Leon (415) 476-2958: [email protected]
A021602: Randomized, Double-Blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors after Progression on Everolimus (CABINET)
Contact: Bryan Le (415) 502-6313: [email protected]
NON-THERAPEUTIC
CC#124512: Banking of Human Biological Specimens for Hepatobiliary Cancer Research Studies: UCSF Hepatobiliary Tissue Bank and Registry
Contact: Karen Zhang (415) 502-1877: [email protected]
CC#134510: GIMP: Molecular Profiling in Gastrointestinal Malignancies
Contact: Dalila Stanfield (415) 476-2976: [email protected]
CC#134510: GIMP: Tissue GIMP & Blood GIMP (Collisson)
Contact: Karen Zhang (415) 502-1877: [email protected]
CC#154520: Lifestyle and Outcomes after Gastrointestinal Cancer: A Prospective Cohort Study (LOGIC)
Contact: Dalila Stanfield (415) 476-2976: Dalil[email protected]
CC#174527: GO – Gut Microbiome and Oral Fluoropyrimidine Study in Patients with Colorectal Cancer
Contact: Dalila Stanfield (415) 476-2976: [email protected]
CC#194520: e-NET: A Pilot Study Using a Web-Based Health Platform to Investigate Health-Related Quality of Life in Patients with Neuroendocrine Tumors
Contact: Julia Whitman (415) 353-7683: [email protected]
https://enet.eurekaplatform.org/
CC#204513: Exploring the Role of the Intestinal Microbiome in Mediating Treatment Outcomes for Patients with Locally Advanced or Metastatic Pancreatic Cancer
Contact: Taylor Sanchez (415) 885-7740: [email protected]
CC#204516: A National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (PLC)
Contact: Karen Zhang (415) 502-1877: [email protected]
CC#204518: BESPOKE Study of ctDNA-Guided Therapy in Colorectal Cancer
Contact: Faaiz Ibrahim (415) 514-8101: [email protected]
CC#184519: Cell Free DNA and Imaging in Advanced Gastrointestinal Cancers
Contact: Taylor Sanchez (415) 885-7740: [email protected]
CC#21453: Demoralization and Depression in Pancreatic Cancer Patients
Contact: Maxine Hamilton (415) 476-3755: [email protected]
CC#214516: NABPLAGEM Pancreatic Cancer Registry Protocol
Contact: Dr. Erica Tsang: [email protected]
PANCREATIC
CC#189513: A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and IN combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma
Contact: Amrutha Sugetur: [email protected]
CC#19704 Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination with Pembrolizumab or Chemotherapy in Patients with Lymphoma or Solid Tumor Malignancies
Contact: Maria Conti (415) 514-2259: [email protected]
CC#20456: Precision Promise Platform Trial For Metastatic Pancreatic Cancer
Contact: Nancy Kaushal (415) 514-7633: [email protected]
A021806: A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Contact: Bryan Le (415) 502-6313: [email protected]
CC#21459: A Multicenter, Open-label, ExploRatory Platform Trial to EValuate ImmunOtherapy Combinations with Chemotherapy for the Treatment of Patients with Previously Untreated Metastatic Pancreatic AdenOcarciNoma (REVOLUTION)
Contact: Taylor Sanchez (415) 885-7740: [email protected]
**************************************************
**TO BE OPENED WITHIN 3 MONTHS**
CC#19801: Digital Symptom Tracking, Patient Engagement and Quality of Life in Advanced Cancer
Contact: Ashna Sethi (415) 353-1745: [email protected]
CC#194522: Phase II Study of Hypofractionated Radiation Therapy to Augment Immune Response in Patients with Metastatic Gastrointestinal Malignancies Progressing on Immune Therapy (ARM-GI)
Contact: Kelly Bauer (415) 514-5633: [email protected]
CC#204517: A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Advanced Liver Cancers (Morpheus-Liver)
Contact: Kelly Bauer (415) 514-5633: [email protected]
CC# 204521: LOXO-IDH-20002 A Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 Mutations
Contact: Kelly Bauer (415) 514-5633: [email protected]
A021901: Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors
Contact: Faaiz Ibrahim (415) 514-8101: [email protected]
CC#209516: Phase II Trial of Targeted Therapies or Immunotherapy as a Single Agent or in Rational in Patients with Advanced Solid Tumors Harboring Specific Mutations or who are TMB-High
Contact: Michelle Howell (415) 514-6248: [email protected]
CC#21454: Phase 2 Study of Cabozantinib Combined with Pembrolizumab in Metastatic or Recurrent Gastric and Gastroesophageal Adenocarcinoma (mGC)
Contact: Alex Milloy (415) 502-3310: [email protected]
CC#21456: Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Colorectal Cancer Survivors (Tools To Be Fit)
Contact: Quincy Harris (415) 353-9544: [email protected]
CC#21981: Understanding barriers to uptake of integrative oncology among Black patients with cancer
Contact: Paige Steiding (415) 514-6314: [email protected]
CC#214513: Navigating a Whole Genome vs. Panel Approach for Patients with Advanced Pancreatic Cancer
Contact: Paige Steiding (415) 514-6314: [email protected]
CC# 214515: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors
Contact: Kelly Bauer (415) 514-5633: [email protected]
CC#214519: Evaluation of a Pilot Integrated Rectal Cancer Exercise Program (REP’s)
Contact: Paige Steiding (415) 514-6314: [email protected]
CC#209518: A Phase 1, Open-label, Multi-Center, Dose-Finding, Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 in Participants with Selected Advanced or Metastatic Solid Tumor Malignancies
Contact: Swati Sudarsan: [email protected], Nana Poku: [email protected]
CC#21951: LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-Randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients with an Advanced Solid Tumor
Contact: Swati Sudarsan: [email protected], Nana Poku: [email protected]
For information on Early Phase clinical trials not listed please contact:
Erika Zigman (415) 353-7381: [email protected]
For information on Immunotherapy trials not listed please contact: Andrew Chon (415) 476-2351: [email protected]